Physician profile
James Goode
NPI 1134671878
$1,870.94
in general payments reported to CMS, 2019-2025
21 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $574 · 2022: $467 · 2023: $346 · 2024: $300 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $471.26 | 2021-2025 | Euflexxa |
| Gotham Surgical Solutions & Devices, INC. | $255.78 | 2021 | |
| Amgen INC. | $219.30 | 2021-2025 | Evenity, Prolia, Krystexxa |
| Smith+Nephew, INC. | $155.59 | 2021-2024 | Bioinductive Implant With Arthroscopic Delivery System - Medium, Q-Fix, Healicoil |
| Depuy Synthes Sales INC. | $148.45 | 2021-2024 | Monovisc, Orthovisc |
| Pacira Therapeutics, INC. | $114.25 | 2021 | |
| Bioventus LLC | $82.64 | 2022-2024 | Exogen Ultrasound Bone Healing System |
| Kowa Pharmaceuticals America, INC. | $59.72 | 2022 | |
| Zimmer Biomet Holdings, INC. | $43.04 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Fidia Pharma USA INC. | $39.35 | 2022-2023 | Triluron, Hymovis |
| Kci USA, INC. | $38.01 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $34.28 | 2025 | |
| Endo Pharmaceuticals INC. | $31.98 | 2022-2024 | Xiaflex |
| Misonix INC | $31.93 | 2021 | |
| Becton, Dickinson and Company | $30.44 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $27.98 | 2023 | Grpro 2.1 |
| Abbvie INC. | $20.51 | 2025 | |
| Ibsa Pharma INC. | $19.70 | 2024 | Tirosint, Licart |
| Djo, LLC | $16.31 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.21 | 2023 | Zilretta |
| Baudax Bio INC. | $14.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Goode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.